Autres langues Castle Biosciences, Inc.

Actions

CSTL

US14843C1053

Equipement, fournitures et distribution médicale

Marché Fermé - Nasdaq 22:00:00 09/10/2026			Varia. 5j.	Varia. 1 janv.
34,42 ^USD	+2,11%		-3,21%	-11,52%

30/09	Castle Biosciences, Inc. présente de nouvelles données sur DecisionDx-Melanoma lors du congrès 2026 de l’Académie européenne de dermatologie et de vénéréologie	CI
24/09	Castle Biosciences, Inc. annonce la publication d’une nouvelle étude mettant en évidence le besoin clinique d’un accompagnement moléculaire dans le choix des traitements de la dermatite atopique, renforçant la valeur d’AdvanceAD-Tx	CI

Autres langues

30/09	Castle Biosciences, Inc. Presents New Data On DecisionDx-Melanoma At The European Academy Of Dermatology And Venereology Congress 2026
24/09	Castle Biosciences, Inc. Announces Publication of New Study Highlighting Clinical Need for Molecular Guidance in Atopic Dermatitis Treatment Selection, Reinforcing the Value of Advancead-Tx
22/09	Castle Biosciences to Open New Lab in Arizona
22/09	Castle Biosciences, Inc. Opens New Laboratory and Office Facility in Scottsdale, Arizona
15/09	Castle Biosciences Publishes Decision Modeling Study Demonstrating Tissuecypher Barrett's Esophagus Test Significantly Improves Risk-Aligned Management for Patients with Barrett's Esophagus
10/09	Castle Biosciences, Inc. - JAAD Publication Shows Improved Performance of DecisionDx-SCC
09/09	Castle Biosciences, Inc. Announces Enhanced Performance Of DecisionDx-SCC With Integration Of Clinicopathologic Risk Factors
08/09	SciBase receives additional order from Castle Biosciences, advancing the collaboration
27/08	Castle Biosciences Insider Sold Shares Worth $317,112, According to a Recent SEC Filing
17/08	Castle Biosciences Gets Approval for Dual Listing on Nasdaq Texas
17/08	Castle Biosciences : Approved for Dual Listing on Nasdaq Texas
30/07	Earnings Flash (CSTL) Castle Biosciences Posts Q2 Revenue of $103.5 Million, vs. FactSet Est of $86.2 Million
30/07	Earnings Flash (CSTL) Castle Biosciences Posts Q2 Adjusted EPS -$0.07, vs. FactSet Est of -$0.41
30/07	Castle Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
30/07	Castle Biosciences Raises Earnings Guidance for the Year 2026
23/07	Castle Biosciences to Present at the Canaccord Genuity 46th Annual Growth Conference
15/07	Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test
14/07	Castle Biosciences Gets New York State Department of Health Approval of AdvanceAD-Tx Test
14/07	Castle Biosciences Receives New York State Department of Health Approval for Advancead-Tx Test
09/07	Castle Biosciences : to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026
25/06	Castle Biosciences : DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
25/06	Castle Biosciences, Inc. Publishes Prospective Study Demonstrating Decisiondx-Melanoma's I31-Slnb Test Outperforms Mia Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
16/06	Castle Biosciences Tissuecypher Barrett's Esophagus Test Surpasses 100,000 Clinical Test Orders
10/06	First Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBase
10/06	SciBase Holding AB and Castle Biosciences Enroll First Patient in New Study Assessing Early Prediction of Flares in Atopic Dermatitis